Table 1.
General information of participants in the Biomarker Identification, Biomarker Validation, and Biomarker Application Cohorts.
| I: Biomarker Identification Cohort | II: Biomarker Validation Cohort | III: Biomarker Application Cohort | |||||
|---|---|---|---|---|---|---|---|
| Characteristic | ATB | LTBI | CON | ATB | LTBI | CON | Patients suspected of ATB |
| N | 28 | 25 | 31 | 51 | 44 | 35 | 147 |
| Median age (range) | 41 (21–62) | 43 (23–65) | 39 (32–58) | 45 (18–71) | 43 (23–67) | 41 (21–64) | 44 (28–71) |
| Men, n (%) | 16 (57.1%) | 13 (52.0%) | 16 (51.6%) | 31 (60.8%) | 25 (56.8%) | 19 (54.3%) | 83 (56.5%) |
| HIV infected, n (%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2.0%) | 0 (0%) | 0 (0%) | 1 (0.6%) |
| BCG Status | |||||||
| Vaccinated | 19 (67.9%) | 18 (72.0%) | 24 (77.4%) | 36 (70.6%) | 35 (79.5%) | 27 (77.1%) | 109 (74.1%) |
| Unvaccinated | 9 (32.1%) | 7 (28.0%) | 7 (22.6%) | 15 (29.4%) | 9 (20.5%) | 8 (22.9%) | 38 (25.9%) |
| T-SPOT results | |||||||
| Negative | 3 (10.7%) | 0 (0%) | 31 (100%) | 6 (11.8%) | 0 (0%) | 35 (100%) | 24 (35.8%) |
| Positive | 25 (89.3%) | 25 (100%) | 0 (0%) | 45 (88.2%) | 44 (100%) | 0 (0%) | 43 (64.2%) |
| Extrapulmonary TB | 6 (21.4%) | – | – | 16 (31.3%) | – | – | 12 (8.2%) |
| Microbiologic test | |||||||
| AFB positive | 23 (82.1%) | 0 (0%) | 0 (0%) | 41 (80.4%) | 0 (0%) | 0 (0%) | 32 (21.8%) |
| Culture positive | 20 (71.4%) | – | – | 38 (74.5%) | – | 46 (31.3%) | |
ATB, active TB patients; LTBI, subjects with latent TB infection; CON, TB-uninfected controls.